TY  - GEN
AU  - Forero-Torres,Andres
AU  - Ramchandren,Radhakrishnan
AU  - Yacoub,Abdulraheem
AU  - Wertheim,Michael S
AU  - Edenfield,William J
AU  - Caimi,Paolo
AU  - Gutierrez,Martin
AU  - Akard,Luke
AU  - Escobar,Carolina
AU  - Call,Justin
AU  - Persky,Daniel
AU  - Iyer,Swaminathan
AU  - DeMarini,Douglas J
AU  - Zhou,Li
AU  - Chen,Xuejun
AU  - Dawkins,Fitzroy
AU  - Phillips,Tycel J
TI  - Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies
SN  - 1528-0020
PY  - 2019///1223
KW  - Adult
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Drug Administration Schedule
KW  - Female
KW  - Humans
KW  - Leukemia, B-Cell
KW  - drug therapy
KW  - Lymphoma, B-Cell
KW  - Male
KW  - Middle Aged
KW  - Protein Kinase Inhibitors
KW  - administration & dosage
KW  - Pyrazoles
KW  - Pyrimidines
KW  - Pyrrolidines
KW  - Salvage Therapy
KW  - methods
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1182/blood-2018-08-867499
ER  -